- Home
- Publications
- Publication Search
- Publication Details
Title
Chronic myeloid leukaemia
Authors
Keywords
-
Journal
LANCET
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-08-21
DOI
10.1016/s0140-6736(21)01204-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia
- (2020) Qian Jiang et al. BLOOD
- Long‐term results of frontline dasatinib in chronic myeloid leukemia
- (2020) Abhishek Maiti et al. CANCER
- Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia
- (2020) Lucia Masarova et al. CANCER
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- (2020) A. Hochhaus et al. LEUKEMIA
- Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial
- (2020) Shinya Kimura et al. Lancet Haematology
- Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study
- (2020) Jorge E. Cortes et al. LEUKEMIA
- High-risk additional chromosomal abnormalities at low blast counts herald death by CML
- (2020) Rüdiger Hehlmann et al. LEUKEMIA
- How to manage CML patients with comorbidities
- (2020) Jorge Cortes BLOOD
- Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience
- (2020) Rita Assi et al. LEUKEMIA & LYMPHOMA
- Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
- (2019) Kamal Chamoun et al. Journal of Hematology & Oncology
- The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
- (2019) Michele Baccarani et al. LEUKEMIA
- Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
- (2019) Koji Sasaki et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Modelling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission
- (2019) Naranie Shanmuganathan et al. BLOOD
- Generic imatinib in chronic myeloid leukemia treatment: long-term follow-up
- (2019) Irena Ćojbašić et al. Clinical Lymphoma Myeloma & Leukemia
- Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia
- (2019) Jorge E. Cortes et al. CURRENT MEDICAL RESEARCH AND OPINION
- Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia
- (2019) Kiran Naqvi et al. CANCER
- Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt)
- (2019) Koji Nagafuji et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Treatment patterns and deep molecular response in chronic phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study
- (2019) Jorge Cortes et al. LEUKEMIA & LYMPHOMA
- Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
- (2019) Iman Abou Dalle et al. Cancer Medicine
- Sudden blastic transformation in treatment‐free remission chronic myeloid leukaemia
- (2019) Mansour Alfayez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study
- (2019) Neil P. Shah et al. LEUKEMIA & LYMPHOMA
- Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study
- (2019) Simona Soverini et al. BLOOD
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
- (2019) Timothy P. Hughes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study
- (2018) Dong-Wook Kim et al. ANNALS OF HEMATOLOGY
- Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase
- (2018) François-Xavier Mahon et al. ANNALS OF INTERNAL MEDICINE
- Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
- (2018) Jorge E. Cortes et al. BLOOD
- Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high risk disease
- (2018) Susan Branford et al. BLOOD
- Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study
- (2018) Carlo Gambacorti-Passerini et al. HAEMATOLOGICA
- Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
- (2018) Naoto Takahashi et al. HAEMATOLOGICA
- Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
- (2018) David M. Ross et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
- (2018) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
- (2018) Susanne Saussele et al. LANCET ONCOLOGY
- Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia
- (2018) Thomas Ernst et al. LEUKEMIA
- Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study
- (2018) Carlo Gambacorti-Passerini et al. HAEMATOLOGICA
- Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
- (2018) Naoto Takahashi et al. HAEMATOLOGICA
- Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia
- (2018) Timothy P. Hughes et al. HAEMATOLOGICA
- Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
- (2018) Oliver Ottmann et al. Blood Cancer Journal
- Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
- (2018) Jorge E. Cortes et al. Journal of Hematology & Oncology
- Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy
- (2018) Massimiliano Bonifacio et al. LEUKEMIA RESEARCH
- Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
- (2017) T P Hughes et al. LEUKEMIA
- Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
- (2017) R Hehlmann et al. LEUKEMIA
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
- (2016) Jorge E. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034
- (2016) Neil P. Shah et al. AMERICAN JOURNAL OF HEMATOLOGY
- Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib
- (2016) Jorge E. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Management of CML-blast crisis
- (2016) Rüdiger Hehlmann et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors
- (2016) P. Jain et al. BLOOD
- Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
- (2016) W. Wang et al. BLOOD
- Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
- (2016) Delphine Rea et al. BLOOD
- Moving treatment-free remission into mainstream clinical practice in CML
- (2016) Timothy P. Hughes et al. BLOOD
- Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study
- (2016) Jorge E. Cortes et al. Clinical Lymphoma Myeloma & Leukemia
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
- (2016) Hannah Bower et al. JOURNAL OF CLINICAL ONCOLOGY
- Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale
- (2016) N C P Cross et al. LEUKEMIA
- Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
- (2016) M Ilander et al. LEUKEMIA
- Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
- (2016) M B Miranda et al. LEUKEMIA
- Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
- (2016) V S Hoffmann et al. LEUKEMIA
- Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
- (2016) A Hochhaus et al. LEUKEMIA
- Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial
- (2016) Jorge E Cortes et al. Lancet Haematology
- Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival
- (2016) Jonathan Douxfils et al. JAMA Oncology
- Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors
- (2015) Carlo Gambacorti-Passerini et al. AMERICAN JOURNAL OF HEMATOLOGY
- The impact of dasatinib on pregnancy outcomes
- (2015) Jorge E. Cortes et al. AMERICAN JOURNAL OF HEMATOLOGY
- Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML
- (2015) Alice Fabarius et al. ANNALS OF HEMATOLOGY
- Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia
- (2015) Delphine Rea ANNALS OF HEMATOLOGY
- Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV
- (2015) S. Saussele et al. BLOOD
- Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era
- (2015) Niklas Gunnarsson et al. BRITISH JOURNAL OF HAEMATOLOGY
- Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
- (2015) Musa Yilmaz et al. CANCER
- The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia
- (2015) David S Sanford et al. Expert Review of Anticancer Therapy
- Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
- (2015) M Pfirrmann et al. LEUKEMIA
- Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
- (2015) A Hochhaus et al. LEUKEMIA
- Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
- (2015) Koji Sasaki et al. Lancet Haematology
- Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial
- (2015) Jun Imagawa et al. Lancet Haematology
- Bosutinibversusimatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
- (2014) Tim H. Brümmendorf et al. BRITISH JOURNAL OF HAEMATOLOGY
- Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Discontinuation of Imatinib: A Tyrosine Kinase Inhibitor Withdrawal Syndrome?
- (2014) Johan Richter et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
- (2013) D. M. Ross et al. BLOOD
- HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia
- (2013) Paolo Strati et al. CANCER
- Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia
- (2013) Alireza Eghtedar et al. Clinical Lymphoma Myeloma & Leukemia
- Tyrosine Kinase Inhibitors as Initial Therapy for Patients With Chronic Myeloid Leukemia in Accelerated Phase
- (2013) Maro Ohanian et al. Clinical Lymphoma Myeloma & Leukemia
- Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
- (2012) F J Giles et al. LEUKEMIA
- Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies
- (2011) D. Verma et al. BLOOD
- Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
- (2011) J. Hasford et al. BLOOD
- Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
- (2011) H. M. Kantarjian et al. BLOOD
- Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
- (2011) P D le Coutre et al. LEUKEMIA
- Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
- (2010) N. P. Shah et al. HAEMATOLOGICA
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP
- (2009) N. Testoni et al. BLOOD
- Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
- (2009) E. Jabbour et al. BLOOD
- Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
- (2009) S. Saussele et al. BLOOD
- The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
- (2009) R. J. Garg et al. BLOOD
- HLA-Identical Sibling Compared With 8/8 Matched and Mismatched Unrelated Donor Bone Marrow Transplant for Chronic Phase Chronic Myeloid Leukemia
- (2009) Mukta Arora et al. JOURNAL OF CLINICAL ONCOLOGY
- The effects of imatinib on pregnancy outcome
- (2008) S. M. Pye et al. BLOOD
- Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
- (2008) Sara Redaelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
- (2008) J Cortes et al. LEUKEMIA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started